http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 26 May 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Glucotrack+to+Highlight+Implantable+Continuous+Blood+Glucose+Monitoring+Technology+at+the+American+Diabetes+Association%E2%80%99s+2026+Scientific+Sessions/26546077.html <p align="left">RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.</p> <p align="left">As part of the ADA’s Innovation Hub, Mark Tapsak, PhD, Glucotrack’s Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses http://www.streetinsider.com/Press+Releases/Glucotrack+to+Highlight+Implantable+Continuous+Blood+Glucose+Monitoring+Technology+at+the+American+Diabetes+Association%E2%80%99s+2026+Scientific+Sessions/26546077.html Tue, 26 May 2026 08:00:00 -0400 GCTK GCTK http://www.streetinsider.com/Press+Releases/Glucotrack+to+Highlight+Implantable+Continuous+Blood+Glucose+Monitoring+Technology+at+the+American+Diabetes+Association%E2%80%99s+2026+Scientific+Sessions/26546077.html <p align="left">RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.</p> <p align="left">As part of the ADA’s Innovation Hub, Mark Tapsak, PhD, Glucotrack’s Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses http://www.streetinsider.com/Press+Releases/Glucotrack+to+Highlight+Implantable+Continuous+Blood+Glucose+Monitoring+Technology+at+the+American+Diabetes+Association%E2%80%99s+2026+Scientific+Sessions/26546077.html Tue, 26 May 2026 08:00:00 -0400 GCTK GCTK http://www.streetinsider.com/Globe+Newswire/Glucotrack+to+Highlight+Implantable+Continuous+Blood+Glucose+Monitoring+Technology+at+the+American+Diabetes+Association%E2%80%99s+2026+Scientific+Sessions/26546077.html <p align="left">RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.</p> <p align="left">As part of the ADA’s Innovation Hub, Mark Tapsak, PhD, Glucotrack’s Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses http://www.streetinsider.com/Globe+Newswire/Glucotrack+to+Highlight+Implantable+Continuous+Blood+Glucose+Monitoring+Technology+at+the+American+Diabetes+Association%E2%80%99s+2026+Scientific+Sessions/26546077.html Tue, 26 May 2026 08:00:00 -0400 GCTK GCTK http://www.streetinsider.com/Globe+Newswire/Glucotrack+to+Highlight+Implantable+Continuous+Blood+Glucose+Monitoring+Technology+at+the+American+Diabetes+Association%E2%80%99s+2026+Scientific+Sessions/26546077.html <p align="left">RUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026.</p> <p align="left">As part of the ADA’s Innovation Hub, Mark Tapsak, PhD, Glucotrack’s Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses http://www.streetinsider.com/Globe+Newswire/Glucotrack+to+Highlight+Implantable+Continuous+Blood+Glucose+Monitoring+Technology+at+the+American+Diabetes+Association%E2%80%99s+2026+Scientific+Sessions/26546077.html Tue, 26 May 2026 08:00:00 -0400 GCTK GCTK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+15/26507114.html si-local-file:///var/storage/secattach/20260515/26507114.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+15/26507114.html Fri, 15 May 2026 16:46:00 -0400 GCTK O.01163441 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+15/26507114.html si-local-file:///var/storage/secattach/20260515/26507114.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+15/26507114.html Fri, 15 May 2026 16:46:00 -0400 GCTK O.01163441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Glucotrack%2C+Inc.+++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502073.html si-local-file:///var/storage/secattach/20260515/26502073.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Glucotrack%2C+Inc.+++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502073.html Fri, 15 May 2026 11:18:00 -0400 GCTK O.01163441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Glucotrack%2C+Inc.+++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502073.html si-local-file:///var/storage/secattach/20260515/26502073.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Glucotrack%2C+Inc.+++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502073.html Fri, 15 May 2026 11:18:00 -0400 GCTK O.01163441 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Glucotrack%2C+Inc.++++++++++For%3A+Mar+31/26496845.html si-local-file:///var/storage/secattach/20260514/26496845.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Glucotrack%2C+Inc.++++++++++For%3A+Mar+31/26496845.html Thu, 14 May 2026 17:28:00 -0400 GCTK O.01163441 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Glucotrack%2C+Inc.++++++++++For%3A+Mar+31/26496845.html si-local-file:///var/storage/secattach/20260514/26496845.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Glucotrack%2C+Inc.++++++++++For%3A+Mar+31/26496845.html Thu, 14 May 2026 17:28:00 -0400 GCTK O.01163441 http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Press+Releases/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html <p align="center"><i>Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology</i></p> <p align="center"><i>Company targeting U.S. clinical trial launch in second half of 2026</i></p> <p align="center"><i>Peer-Reviewed Stud</i><i>ies</i> <i>published </i><i>in </i><i>The Journal of Diabetes Research and in </i><i>the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support </i><i>advancement of Company’s</i><i> implantable </i><i>CBGM technology</i></p> <p align="justify">Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the http://www.streetinsider.com/Globe+Newswire/Glucotrack+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26496823.html Thu, 14 May 2026 17:27:00 -0400 A.06822034 A.27522912 GCTK O.01163441 O.20026344 O.35385627 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+14/26496834.html si-local-file:///var/storage/secattach/20260514/26496834.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+14/26496834.html Thu, 14 May 2026 17:27:00 -0400 GCTK O.01163441 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+14/26496834.html si-local-file:///var/storage/secattach/20260514/26496834.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+14/26496834.html Thu, 14 May 2026 17:27:00 -0400 GCTK O.01163441 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+07/26453105.html si-local-file:///var/storage/secattach/20260507/26453105.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Glucotrack%2C+Inc.++++++++++For%3A+May+07/26453105.html Thu, 07 May 2026 16:07:00 -0400 GCTK O.01163441